06:09:09 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Navamedic är ett norskt läkemedelsbolag. Bolaget licensierar, marknadsför och säljer hälso- och farmaceutiska produkter till sjukhus, forskningsinstitut samt apotek. Största delen av produktportföljen består av renodlade läkemedel, hälsotillskott och hälsoprodukter som används för behandling av ett flertal olika patientbesvär inom dermatologi, urologi samt gynekologi. Verksamhet innehas inom den skandinaviska marknaden. Bolaget etablerades 1999 och har sitt huvudkontor i Lysaker.

Kalender

2021-11-04 Kvartalsrapport 2021-Q3
2021-08-13 Kvartalsrapport 2021-Q2
2021-06-04 Ordinarie utdelning NAVA 0.00 NOK
2021-06-03 Årsstämma 2021
2021-05-11 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-04 Ordinarie utdelning NAVA 0.00 NOK
2020-06-03 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-03-11 Extra Bolagsstämma 2020
2020-02-13 Bokslutskommuniké 2019
2019-11-01 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning NAVA 0.00 NOK
2019-05-28 Årsstämma 2019
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-12-20 Extra Bolagsstämma 2018
2018-11-09 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-06-08 Ordinarie utdelning NAVA 0.00 NOK
2018-06-07 Årsstämma 2018
2018-05-30 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-07-28 Kvartalsrapport 2017-Q2
2017-06-07 Ordinarie utdelning NAVA 0.00 NOK
2017-06-06 Årsstämma 2017
2017-05-10 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2017-01-13 Extra Bolagsstämma 2017
2016-11-11 Kvartalsrapport 2016-Q3
2016-08-18 Kvartalsrapport 2016-Q2
2016-06-21 Ordinarie utdelning NAVA 0.00 NOK
2016-06-20 Årsstämma 2016
2016-05-11 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-10-30 Kvartalsrapport 2015-Q3
2015-10-30 Extra Bolagsstämma 2015
2015-08-21 Kvartalsrapport 2015-Q2
2015-06-09 Ordinarie utdelning NAVA 0.00 NOK
2015-06-08 Årsstämma 2015
2015-04-28 Kvartalsrapport 2015-Q1
2015-02-27 Bokslutskommuniké 2014
2014-10-31 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2
2014-06-10 Årsstämma 2014
2014-05-06 Kvartalsrapport 2014-Q1
2014-02-27 Bokslutskommuniké 2013
2013-11-01 Kvartalsrapport 2013-Q3
2013-08-30 Kvartalsrapport 2013-Q2
2013-06-13 Kapitalmarknadsdag 2013
2013-05-23 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-15 Bokslutskommuniké 2012
2012-02-10 Bokslutskommuniké 2011
2011-10-21 Kvartalsrapport 2011-Q3
2011-08-25 Kvartalsrapport 2011-Q2
2011-05-05 Kvartalsrapport 2011-Q1
2011-04-14 Årsstämma 2011
2011-02-04 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-26 Kvartalsrapport 2010-Q2
2010-05-05 Kvartalsrapport 2010-Q1
2010-03-25 Årsstämma 2010
2010-02-11 Bokslutskommuniké 2009
2021-05-07 14:22:51
Oslo 7 May 2021 - Navamedic ASA ("Navamedic", OSE: NAVA) announces it has signed
an agreement with Icepharma for distribution of the antibiotics products to the
Icelandic market.

As announced on 4 August 2020, Navamedic completed the acquisition of marketing
authorisations in the Nordics for a portfolio of antibiotics products. The
antibiotics in the portfolio, now fully onboarded on Navamedic's platform, are
designed to be given intravenously to patients and are in regular use in
hospitals in all the Nordic countries.

In accordance with the plan to roll out antibiotics in the Nordic region,
Navamedic has signed an agreement with Icepharma for distribution of the
antibiotics products to the Icelandic market.

"The addition of the antibiotics portfolio marked an important milestone for
Navamedic and our expanding hospital and prescription drug offering. We are
pleased to welcome Icepharma to join us in securing steady supply of these
important products to Nordic hospitals," says Kathrine Gamborg Andreassen, CEO
of Navamedic.

The antibiotics in the portfolio are designed to be given intravenously to
patients and are currently in regular use in hospitals in all the Nordic
countries with an annual turnover of approximately NOK 25 million. This
portfolio will strengthen NavamedicŽs hospital offering with an important
product range. This is an important step in NavamedicŽs growth strategy.

Navamedic has recruited Janne Folmoe to the company's Specialty Pharma
commercial team. Folmoe comes with extensive experience from the ACS Dobfar
portfolio with focus on tender management, and previous commercial positions in
the pharma industry in companies such as Bayer and Mylan. Folmoe will play a key
role in the commercial operation with regards to the antibiotics portfolio.

For more information, please contact:
Kathrine Gamborg Andreassen, CEO of Navamedic ASA
kathrine@navamedic.com

Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic ASA
+46 70 257 99 71
alexander.lidmejer@navamedic.com

About Navamedic

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com